Clinical development of an siRNA drug for KRAS-mutant cancers
First written in FY2019-Q3. 3 of 7 entries say "Advanced", first in FY2019. Latest entry: FY2026.
No other company in this theme has enough history to compare yet.
- FY2026SoftenedAnnual report
「With respect to activities aimed at out-licensing drugs for the treatment of refractory cancer, the company will determine its course of action while taking the business environment and other factors into account.」
The wording concerning out-licensing the drug for refractory cancer changed from continuing activities to determining the direction while taking the business environment into consideration. - 2026-04-27SoftenedEarnings
「With respect to activities aimed at out-licensing drugs for the treatment of refractory cancer, the company will determine its course of action while taking the business environment and other factors into account.」
The wording changed from continuing activities aimed at out-licensing to determining the course of action in light of the business environment. - FY2026-H1RestatedAnnual report
「In the discovery of nucleic acid therapeutics, the clinical Phase 1 trial for the drug for treatment of refractory cancer was completed in the first quarter of the previous consolidated fiscal year, and we will continue working toward out-licensing.」
The disclosure reconfirms that the Phase 1 trial for the drug for refractory cancer was completed in the first quarter of the previous fiscal year and that efforts toward out-licensing will continue. - FY2025-H1AdvancedAnnual report
「In nucleic acid therapeutics drug discovery, the Phase 1 clinical trial for the refractory cancer treatment was completed during the first quarter of the consolidated fiscal period, and the company will continue activities toward out-licensing.」
For the drug for refractory cancer, development has progressed from the previous expectation of completing the Phase 1 trial to the stage where completion of the trial is now reported. - FY2024AdvancedAnnual report
「The clinical Phase 1 trial for the drug for treatment of refractory cancer is expected to be completed.」
Development of the drug for refractory cancer has progressed to the stage at which completion of the Phase 1 trial is expected. - FY2019AdvancedAnnual report
「During the current consolidated fiscal year, the Company obtained authorization from the U.S. FDA (Food and Drug Administration) to conduct clinical trials for a new nucleic acid therapeutic targeting KRAS-mutant cancers and commenced a Phase 1 clinical trial.」
A Phase 1 clinical trial was commenced for the siRNA formulation targeting KRAS-mutant cancers after obtaining FDA authorization. - FY2019-Q3First statedAnnual report
「In nucleic acid therapeutics drug discovery, an siRNA formulation targeting KRAS-mutated cancers was authorized by the U.S. FDA (Food and Drug Administration) for clinical trial implementation and will proceed to a Phase 1 clinical trial.」
A new development program has emerged for an siRNA formulation targeting KRAS-mutant cancers, following receipt of authorization from the U.S. FDA to conduct clinical trials and advancement to Phase 1.